SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating

Key Points

• Wall Street Zen upgraded SAB Biotherapeutics from “strong sell” to “sell,” while the broader analyst consensus remains “Moderate Buy,” based on nine Buy, one Hold, and one Sell rating.
• Analysts’ consensus price target is $12.00, well above the stock’s $3.90 opening price; targets from other firms range from $10 to $16.
• SAB reported a quarterly loss of $0.28 per share, in line with estimates, and analysts expect a full-year loss of $1.21 per share. Institutional ownership remains limited at 7.82%, while forecasts differ on how quickly the company may reach profitability.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report issued on Monday.

A number of other brokerages have also recently issued reports on SABS. Jefferies Financial Group started coverage on SAB Biotherapeutics in a report on Wednesday, May 20th. They set a "buy" rating and a $11.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of SAB Biotherapeutics in a report on Monday, June 15th. Barclays assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, June 24th. They set an "overweight" rating and a $13.00 price target for the company. Chardan Capital increased their price objective on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a "buy" rating in a research report on Wednesday, June 17th. Finally, Citigroup started coverage on SAB Biotherapeutics in a research note on Friday, May 22nd. They set a "buy" rating and a $11.00 price objective for the company. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $12.00.

SAB Biotherapeutics Price Performance

SABS opened at $3.90 on Monday. The company has a market capitalization of $354.86 million, a price-to-earnings ratio of -3.00 and a beta of 0.53. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $3.68 and a 200-day moving average price of $3.83. SAB Biotherapeutics has a twelve month low of $1.85 and a twelve month high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28). Equities analysts expect that SAB Biotherapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

Hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. purchased a new position in SAB Biotherapeutics in the 1st quarter worth approximately $29,000. ADAR1 Capital Management LLC bought a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth $30,000. Dimensional Fund Advisors LP bought a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth $32,000. State of Wyoming purchased a new position in SAB Biotherapeutics in the fourth quarter worth $34,000. Finally, Virtu Financial LLC purchased a new position in SAB Biotherapeutics in the third quarter worth $40,000. 7.82% of the stock is currently owned by institutional investors.

Key SAB Biotherapeutics News

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: Brookline Capital Markets raised its FY2030 EPS estimate for SAB Biotherapeutics; the latest report adds to a series of upward revisions, including improved forecasts for fiscal 2027 and 2028 and a shift to projected profitability of $0.48 per share in FY2029. SABS FY2030 EPS Estimate Lifted by Brookline Capital Markets
• Positive Sentiment: Brookline also raised its Q3 and Q4 2026 EPS estimates to a loss of $0.24 per share from losses of $0.25, and improved its FY2027 estimate to a $0.95 loss from a $1.07 loss. These revisions suggest the firm expects losses to narrow faster than previously forecast. Brookline Capital Markets SAB Biotherapeutics estimates
• Neutral Sentiment: HC Wainwright reiterated its “Buy” rating and $10 price target, substantially above the recent trading level. However, its updated projections still call for losses of $1.21 per share in FY2026 and $0.60 in FY2027, compared with the current consensus FY2026 loss estimate of $1.19 per share. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright lowered its Q3 and Q4 2026 EPS estimates to losses of $0.29 and $0.31, respectively, and cut its FY2026 through FY2030 forecasts. The firm now expects a $0.48 loss in both FY2029 and FY2030, indicating a slower path to profitability than Brookline projects. HC Wainwright SAB Biotherapeutics estimates

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source